Stockscreener 앱 받기
4.98
2.89%
0.14
시간 외 거래:
4.98
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan
Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan
Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan
Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan
Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - marketbeat.com
Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com
META_TITLE_QUOTE - Yahoo Finance
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Lexeo Therapeutics advances gene therapy and gains RMAT status - tipranks.com
LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway - TradingView
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020 - Quiver Quantitative
Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary - TradingView
Lexeo Reports $25.9 Million Q2 Net Loss as SUNRISE-FA 2 Begins - Quiver Quantitative
Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash - Stock Titan
Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics (LXEO) Earnings Date and Reports 2026 - marketbeat.com
Lexeo Therapeutics (LXEO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO) - Stock Titan
Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status - AllSci
Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday - MarketBeat
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020 - TradingView
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.com
Lexeo Therapeutics (LXEO) Advances 1.7% to $4.49, Holding Above Key SupportMid Cap Momentum - dars.gov.et
Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy - Bitget
Lexeo wins FDA RMAT status for LX2020 - PharmaTimes
Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC - MarketBeat
Lexeo Therapeutics (LXEO) Pulls Back 5% as Selling Pressure IntensifiesVWAP Deviation - dars.gov.et
Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Strong-Buy at Chardan Capital - MarketBeat
Lexeo Therapeutics Inc (LXEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexeo Therapeutics Inc (LXEO) Balance Sheet - TradingKey
Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexeo Therapeutics Inc (LXEO) Cash Flow - TradingKey
Lexeo Therapeutics, Inc. $LXEO Shares Sold by Octagon Capital Advisors LP - MarketBeat
Lexeo Therapeutics Inc (LXEO) Income Statement - TradingKey
LXEO|Lexeo Therapeutics Inc|Price:4.660|Chg%:-0.050 - TradingKey
Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spruce Street Capital LP Acquires 753,593 Shares of Lexeo Therapeutics, Inc. $LXEO - MarketBeat
LXEO|Lexeo Therapeutics Inc|Price:4.840|Chg%:-0.120 - TradingKey
Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor Focus - TipRanks
Lexeo Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Surprises, Stock Edges DownSubscription Growth Report - dars.gov.et
Lexeo Therapeutics (LXEO) Faces Continued Selling Pressure as Shares Test Key Support LevelsSuperTrend Flip - dars.gov.et
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple - Yahoo Finance
Lexeo Therapeutics (LXEO) Slips 4.55% as Stock Tests Support Near $4.58Channel Projection - dars.gov.et
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (LXEO) Slips 4.55% as Stock Tests Proximity to Key SupportHigh Reward Trades - dars.gov.et
Lexeo Therapeutics Slips 5.3% as Biotech Volatility Weighs on LXEO SharesVolatility Surface - dars.gov.et
Lexeo Therapeutics (LXEO) Edges Higher as Key Support HoldsPassive Flow - dars.gov.et
Have Lexeo Therapeutics Insiders Been Selling Stock? - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI) - The Globe and Mail
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $17 - Moomoo
LXEOLexeo Therapeutics Inc Dividends - Finviz
Have Insiders Sold Lexeo Therapeutics Shares Recently? - simplywall.st
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance
1.80%
1.77%
자본화:
|
볼륨(24시간):